JB25 and JB26 are new HIV-1 nonnucleoside reverse transcriptase inhibitors, and show potent anti-HIV activities.  Sequential passage experiments with wild-type virus were performed to select and identify mutations induced by these two compounds in vitro.  For the initial passage, compounds were present at     approximately 2-fold IC₅₀ in MT-2 cells.  When cytopathic effect (CPE) was observed in more than 75% of the cells, the culture supernatants were collected.  For the subsequent passages, fresh MT-2 cells were infected with 1 mL supernatants from the previous passage (regardless of the virus titer) and cultured in the presence of the compounds at concentrations that were increased 2-fold compared with that in the previous passage.  This  procedure was repeated with increasing concentrations for 12 passages.  JB25 had amino acid substitution L100I (TTA→ATA) at passage 6, and then changed into 100 M (ATA→ATG) at passage 12, which was rare  mutation form and had not been reported.  At the same time, Y188C (TAT→TGT) mutation appeared at passage 10.  For JB26, there was a L100I (TTA→ATA) mutation at passage 10.  In a word, JB25 and JB26 showed a low genetic barrier to the development of resistance, and the resistance to JB26 developed slower than JB25.  The mutations selected by JB25 and JB26 were mainly associated with codons 188 and 100 of HIV-1 reverse transcriptase.